Management of potential brain death organ donors (BDOD) requires strategies to manage severe cardiovascular and metabolic impairment. Terlipressin is a synthetic analog of vasopressin characterized by greater selectivity for the V1 receptor than vasopressin itself. The aim of this case series is to demonstrate if terlipressin reduces the need for noradrenaline in potential BDOD with hemodynamic instability. Terlipressin was utilized in 49 consecutive cases during a 24-month period. Reduction of amine dose was considered as the end point. Norepinephrine mean dose before terlipressin administration was 0.229 mcg/kg/min versus 0.055 mcg/kg/min after treatment (p<0.0001). Our results suggest a role for terlipressin in hormonal replacing therapy in instable BDOD, especially when vasopressin is lacking.
TERLIPRESSIN IN BRAIN DEATH ORGAN DONORS MANAGEMENT REDUCES THE NEED FOR NORADRENALIN CONTINUOUS INFUSION
Piazza O.
Writing – Review & Editing
2019
Abstract
Management of potential brain death organ donors (BDOD) requires strategies to manage severe cardiovascular and metabolic impairment. Terlipressin is a synthetic analog of vasopressin characterized by greater selectivity for the V1 receptor than vasopressin itself. The aim of this case series is to demonstrate if terlipressin reduces the need for noradrenaline in potential BDOD with hemodynamic instability. Terlipressin was utilized in 49 consecutive cases during a 24-month period. Reduction of amine dose was considered as the end point. Norepinephrine mean dose before terlipressin administration was 0.229 mcg/kg/min versus 0.055 mcg/kg/min after treatment (p<0.0001). Our results suggest a role for terlipressin in hormonal replacing therapy in instable BDOD, especially when vasopressin is lacking.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
